Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax (2022 - 2026)

Acadia Pharmaceuticals has reported Long-Term Deferred Tax for 4 years, with the latest figure at $249.6 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $249.6 million; the trailing twelve-month figure through Mar 2026 stood at $249.6 million (changed N/A YoY), and the FY2025 full-year result was $249.9 million, changed N/A from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $249.6 million, roughly flat from $249.9 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $249.9 million in Q4 2025, with the low at $1.2 million in Q4 2022.
• Average Long-Term Deferred Tax over 4 years is $126.9 million, with a median of $128.2 million recorded in 2023.
• Peak annual rise in Long-Term Deferred Tax reached 466.67% in 2023, while the deepest fall reached 466.67% in 2023.
• Tracing ACAD's Long-Term Deferred Tax over 4 years: stood at $1.2 million in 2022, then jumped by 466.67% to $6.8 million in 2023, then surged by 3574.69% to $249.9 million in 2025, then decreased by 0.1% to $249.6 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $249.6 million (Q1 2026), $249.9 million (Q4 2025), and $6.8 million (Q4 2023), per Business Quant data.

Peer Comparison